Pharmaceutical Commerce
JULY 31, 2025
14 This is in the midst of various companies—such as Regeneron, Roche, Merck, and ThermoFisher—reshoring production to the United States in order to avoid paying these hefty tariffs—a process that can take years if the proper infrastructure is not already put in place. UCB to Invest $5 Billion into US Production Plant. June 16, 2025.
Pharmaceutical Commerce
JULY 29, 2025
The tariff is meant to encourage pharma manufacturers to reshore their production back to the United States, which has been in the works for many players, including AstraZeneca, who plans to invest $50 billion by 2030 in US-based drug manufacturing and R&D, marking its largest single manufacturing investment globally.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Commerce
JULY 23, 2025
Companies such as AstraZeneca are committing massive investments, including $50 billion in US manufacturing and R&D by 2030, to strengthen domestic production and mitigate tariff impacts. It will also support our ambition to reach $80 billion in revenue by 2030. Trump Says Pharma Industry Should Expect Tariffs by Aug. Saraceno N.
Pharmaceutical Technology
JULY 14, 2025
Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. The global RSV market is set to reach $6.3bn in value by 2030, according to analysis by GlobalData. MAXSHOT.PL
Pharmaceutical Technology
AUGUST 7, 2025
Meanwhile, GlobalData forecasts that the mRNA vaccine market will continue to grow, increasing in value from $11bn in 2024 to $17.9bn in 2030. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Give your business an edge with our leading industry insights.
Proxsys Rx
APRIL 4, 2024
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Payers and manufacturers control the players in Specialty, so newcomers need significant support and guidance navigating the process.
Proxsys Rx
AUGUST 22, 2023
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Payers and manufacturers control the players in Specialty, so newcomers need significant support and guidance navigating the process.
Expert insights. Personalized for you.
Let's personalize your content